tbuckley/cabot-search huggingface dataset:
INJURIES IN AUSTRALIAN FEMALE CRICKETERS AND THEIR TREATMENT SOURCES: AN ANALYSIS OF SELF-REPORTED SURVEY DATA FROM 2014–15 SEASON
Authors: Nirmala Perera, Alex Kountouris, Joanne Kemp, Corey Joseph, Caroline Finch
Journal: British Journal of Sports Medicine (2017)

Background Cricket is a sport with increasing popularity among women. Most studies examining injury in cricket include only men. In other sports, the types of injuries experienced by men and women are known to be different. Objective To present a profile of self-reported injuries among Australian female cricketers during 2014–15 season. Design Cross-sectional survey. Setting Community to elite level Australian Cricket. Participants Women who were aged 16+years and registered to play senior cricket (ranging from grade to international level). Main Outcome Measurements Incidence, nature, anatomical location of injuries and their treatment sources. Results Of 164 survey respondents (mean age 23.7 years) 43.6% played cricket as all-rounders. 109 players reported being injured; 18% (n=20) sustained ≥3 injuries. Distal lower limb (23%, n=26) and head, neck and spine (22%, n=5) were the most frequently injured locations. The nature of injuries included 30.4% (n=35) muscle injuries; 27.8% (n=32) joint or ligament injuries and 21.7% (n=25) gradual onset/overuse injuries. The majority of injured respondents (43%, n=52) reported receiving treatment from an allied health professional; 29.2% (n=35) opted for self-treatment and 12.5% (n=15) did not seek any treatment. Conclusions This is the first national survey of injuries in female cricketers in Australia. Compared to previous injury figures for women in sports similar to cricket, the current study shows a higher frequency of injury. The most commonly injured anatomical location was the distal lower limb, in contrast to previous studies reporting shoulder and back pain. The high frequency of head, neck and spinal injuries self-reported needs further consideration to determine the specific nature of these injuries, whilst as are the number of injuries that remain untreated is concerning. There are some limitations to the retrospective self-reported nature of this study. However, this study offers a foundation for future monitoring of injuries sustained by female cricketers.
Traitement du reflux biliaire chez des patients gastrectomisés par injection d’un biopolymère: Enteryx™
Authors: R Laugier, J Devière, G Costamagna, JC Letard, A Tringali
Journal: Endoscopy (2004)

Introduction: Si les traitements du reflux acide ont été considérablement améliorés ces dernières années, il n’en est pas de même pour le reflux biliaire chez des patients gastrectomisés. Les seuls médicaments utiles ont une action topique, locale et très transitoire. Ceci entraîne, le plus souvent, des réveils nocturnes et une baisse de la qualité de vie. Patients et Méthodes: Onze patients (5 hommes, 6 femmes, de 51,6 ± 13,2 ans) ont été inclus dans cette étude multicentrique pilote. Ils avaient été gastrectomisés pour cancer 9,9 ans auparavant. La reconstruction était une anastomose oeso-jéjunale quand une petite calotte tubérositaire n’avait pas été laissée en place. A l’inclusion, un score dérivé du Velanovich et un score de qualité de vie étaient réalisés sans traitement. Le biopolymère EnteryxTM (poly-vinyl-alcool) était injecté par voie endoscopique dans le muscle cardial par une aiguille de type »sclérothérapie«: 5,9 mL (4,1–7,7 mL) d’Enteryx ont été injectés en 4,3 (3 à 8) sites, sous contrôle endoscopique et scopique. Le suivi après injection est de 17,9 mois (3 à 24 mois). Résultats: Aucune complication sévère n’a été observée. Deux patients ont présenté une dysphagie qui a nécessité une dilatation endoscopique (ballon de 15mm). Aucun patient n’a été retraité. Le score moyen de brûlures est passé de 29,2 ± 6,7 à 8,1 ± 7,8 (p < 0,05) et celui de régurgitations de 12,8 ± 2,8 à 4,1 ± 5,4 (p < 0,05). Le nombre moyen de réveils nocturnes était passé de 3,5 à 1. Conclusion: Dans cette étude pilote, l’injection intra-cardiale d’Enteryx est apparue simple, sans complication et très efficace sur le soulagement des brûlures oesophagiennes, en particulier nocturnes, ce qui a amélioré considérablement la qualité de vie.
Abstract 277: High Consistency in Left Ventricular 31P-MR Spectra in Rats in vivo Allows Follow-up Detection of Small Variations in Energy Status and Early Energy Defects
Authors: Veronique Deschodt-Arsac, Julie Magat, Jerome Naulin, Bruno Quesson, Pierre Dos Santos, Laurent Arsac
Journal: Circulation Research (2015)

Introduction: Phosphorus magnetic resonance spectroscopy (31P-MRS) makes a unique and valuable contribution to understand how mitochondrial energy supply responds to ATP demand in beating hearts. Changes in PCr/ATP allow detecting energy dysbalance that often predict disease and mortality. However, MR techniques in vivo are challenged by tissue contamination and poor signal-to-noise (S/N) ratio, especially in hearts of rodent models. Methods: Here we optimized acquisition of localized cardiac 31P-MR spectra, obtained with a surface probe at 9.4T in vivo from left ventricle in control and SHR rats. MR spectra (192s) and short-axis cine-MRI frames were obtained during 9-weeks in sinus rhythm and during tachycardia induced by acute injection of isoproterenol (10μg/kg) at week 10. Results: Highly reproducible spectra with low S/N ratio helped demonstrating healthy PCr/ATP despite progressive ventricular hypertrophy in SHR rats. Isoproterenol induced similar tachycardia (425bpm ± 7) but higher drop in PCr/ATP (-17.1% vs. -4.7%, P&lt;0.05) associated with higher recovery time constant (23.9 vs. 7.3 min, P&lt;0.05). Discussion/Conclusion: Our results indicate that SHR rats maintain energy homeostasis during early development of pathology but present a blunted capacity of mitochondrial energy supply to respond to high ATP demand during strong ß-adrenergic activation of the myocardium. The optimization in localized 31P-NMR analysis offer exciting possibilities to better investigate primary precursors detection of cardiac failure in rodent models.
02.31 Targeted inhibition of macrophage inflammatory protein 1-alpha (ccl3) prevents pit formation by human osteoclasts and potently attenuates the erosion of bone in collagen-induced arthritis
Authors: Lauren A Jordan, Benjamin F Fenner, Ruth Davies, Ann K Harvey, Ernest H Choy, Rachel Errington, Maria Bokarewa, Anwen S Williams
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> In patients with rheumatoid arthritis (RA), osteolysis, osteopenia and osteoporosis are predictive of a severe disease phenotype. CCL3 is a chemokine associated with inflammatory osteolytic lesions and bone resorption by osteoclasts in patients with multiple myeloma. CCL3's role in modulating bone destruction during inflammatory arthritis has not been established. The purpose of this study was to assess pharmacological blockade of CCL3 as a strategy to prevent or inhibit osteoclast-associated bone damage during inflammatory arthritis. <h3>Method</h3> Fully differentiated osteoclasts were formed from human CD14-positive mononuclear cell precursors cultured with macrophage-colony stimulating factor (m-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL). Collagen-induced arthritis (CIA) was selected for <i>in vivo</i> studies. Antibodies (anti-CCL3 and isotype control) were tested for their potency to modulate; (i) osteoclast differentiation and resorption of bone substrate <i>in vitro</i> and (ii) arthritis severity, synovial inflammation by histology and bone erosion by x-ray. <h3>Results</h3> The concentration of CCL3 in supernatants increased in a time-dependent manner over the 14-day osteoclast culture period (p&lt;0.05). There was a strong, specific correlation between osteoclast number and CCL3 level (p&lt;0.01). Significant concentration-dependent inhibition of osteoclastogenesis was observed by neutralising CCL3 (p≤0.05). The erosion of ivory discs by osteoclasts was reduced significantly (p≤0.05) by ant-CCL3. Mean area of disc resorbed was 0.2% (anti-CCL3), 0.1% (osteoprotegerin) and 1.5% (Isotype control). Synovial inflammation and joint erosion by histology were both significantly reduced by CCL3 blockade in CIA. The composite histology score was 3.8±0.36 (anti-CCL3) versus 6.8±0.6 (isotype control). Osteoclast number was significantly reduced in the wrist (p&lt;0.05) and elbow (p&lt;0.05) joints by anti-CCL3 blockade. Bone erosion by x-ray in the hind paws (p&lt;0.05) and fore paws (p&lt;0.01) was also significantly reduced by anti-CCL3. <h3>Conclusion</h3> Targeted inhibition of CCL3 protect the synovial joint against arthritis-associated pathology by potent inhibition osteoclast formation and bone erosion. Our data may help guide future innovations for the diagnosis and treatment of inflammatory arthritis.
A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer (RCC).
Authors: Eric A. Singer, Julia C. Friend, Geri Hawks, Cathy Vocke, Adam R. Metwalli, Peter A. Pinto, Gennady Bratslavsky, W. Marston Linehan, Ramaprasad Srinivasan
Journal: Journal of Clinical Oncology (2012)

TPS4680 Background: There are currently no treatment options of proven efficacy for patients with advanced papillary RCC. The evaluation of families with inherited forms of RCC has allowed for the identification of genetic alterations associated with papillary RCC. HLRCC is one such familial condition with a propensity for the development of a clinically aggressive variant of papillary RCC characterized by unique histopathologic features. Germline mutations in the gene for the Krebs cycle enzyme fumarate hydratase (FH) are the genetic hallmark of HLRCC. Mutational inactivation of FH leads to von Hippel-Lindau-independent upregulation of hypoxia inducible factors (HIF) and their downstream transcriptional targets such as vascular endothelial growth factor (VEGF) and transforming growth factor-alpha (TGF-α) / epidermal growth factor receptor (EGFR). Upregulation of the HIF pathway may also be important in sporadic papillary RCC, although the prevalence of FH inactivation in these patients is unknown. We propose to evaluate the activity of dual VEGF/EGFR blockade with bevacizumab/erlotinib in patients with HLRCC-associated RCC and sporadic papillary RCC. Methods: This is a single arm phase II study based on an open label Simon two-stage minmax design with a maximum accrual of 20 patients in each of two cohorts: Cohort 1- patients with HLRCC; Cohort 2- patients with sporadic papillary RCC. The primary endpoint is RECIST overall response rate, assessed independently in each cohort. Patients will receive bevacizumab (10mg/Kg IV every 2 weeks) and erlotinib (150mg PO daily). Dose reductions and drug interruptions for toxicity are allowed. Patients will be evaluated for response every 8 weeks. Major eligibility criteria include: advanced RCC associated with HLRCC or sporadic papillary RCC; age &gt;18 years; ECOG 0-2; measurable disease by RECIST; no brain metastases; no more than 2 prior regimens containing a VEGF inhibitor; and no prior therapy with bevacizumab. The prespecified activity goal for the first stage of accrual has been met for both cohorts. NCT01130519.
MYC protein expression as prognostic in acute myeloid leukemia.
Authors: Maro Ohanian, Uri Rozovski, Hagop M Kantarjian, Sanam Loghavi, Lynne Abruzzo, Zhuang Zuo, Yang Huh, Guillermo Garcia-Manero, Farhad Ravandi, Michael Andreeff, Steven Mitchell Kornblau, Gautam Borthakur, Martin H. Nguyen, Peter Hu, L Jeffrey Medeiros, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Zeev Estrov, Carlos E. Bueso-Ramos, Jorge E. Cortes
Journal: Journal of Clinical Oncology (2016)

7019 Background: Despite the development of new MYC-targeted drugs, few studies have assessed MYC protein expression in acute myeloid leukemia (AML). We assessed MYC expression by immunohistochemistry (MYC-IHC) in bone marrow (BM) specimens from patients (pts) with untreated AML, therapy related myeloid neoplasms (t-MN) and myeloid blast phase of myeloproliferative neoplasms (MB-MPN) and explored the prognostic significance of MYC expression. Methods: AML cases were classified according to WHO 2008. We assessed MYC-IHC on BM core biopsies from 195 cases. MYC expression was assessed by enumerating the percentage of cells showing strong nuclear MYC expression. Results: Overall, mean MYC expression ranged from 6% to 46% among WHO categories: AML without maturation, 46% (range 0-92%;n = 9), acute myelomonocytic leukemia, 44% (range 2-95%; n = 14), AML with t(9;11) 41% range 12-80%;n = 5), AML with minimal differentiation, 35% (range 1-82%; n = 11), AML-not further specified, 30% (range 2-71%; n = 3), acute monoblastic/monocytic leukemia 28% (range 5-70%; n = 10), AML with myelodysplasia-related changes, 28% (range 0-90%; n = 79), t-MN, 26% (range 0-90%; n = 22), MB-MPN, 15% (range 1-40%; n = 8), AML with maturation, 26% (range 0-81%; n = 31), acute erythroid leukemia 9% (range 5-12%; n = 2) and acute megakaryoblastic leukemia 6% (n = 1). MYC-IHC above a determined cutoff of 6% conferred a significantly worse median overall survival (OS) of 10 months (mos) compared to 23 mos in those with MYC-IHC ≤ 6% (p = 0.023). Further, pts with MYC-IHC > 6% had inferior median event-free survival (EFS) of 5 mos vs 11 mos (p = 0.033) in pts with MYC-IHC ≤ 6%. The complete remission (CR) duration was significantly longer (23 mos) for pts with MYC-IHC ≤ 6% versus > 6% (15 mos) (p = 0.054). On multivariate analysis of OS, MYC-IHC retained prognostic significance (p = 0.038) when considering WBC, peripheral blood blasts, treatment, cytogenetic risk groups, Auer rods, performance status, and prior chemotherapy/radiation. On multivariate analysis of event free survival (EFS), MYC-IHC was marginally significant (p = 0.081) Conclusions: MYC overexpression is a strong prognostic factor in untreated AML. High MYC expression confers a significantly inferior OS, EFS, and CR duration.
06.06 Low dose radiation alters the inflammatory phenotype of fibroblast-like synoviocytes and macrophages and stimulates osteoblasts
Authors: Lisa Deloch, Jana Liberg, Michael Rückert, Axel J Hueber, Rainer Fietkau, Benjamin Frey, Udo S Gaipl
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that is characterised by the infiltration of activated immune cells in the synovial joint, followed by progressive destruction of cartilage and bone. Even though there are many effective drug-based treatment options available not all patients do respond satisfactorily. In those cases treatment with low dose radiotherapy (LD-RT) might be an option as previous studies demonstrated that LD-RT attenuates inflammation and pain. In previous experiments using the h<i>TNF-α</i> tg mouse model we discovered that fibroblast-like synoviocytes (FLS) can be altered into an anti-inflammatory phenotype and numbers of differentiated osteoclasts are being reduced by LD-RT. Our <i>in vivo</i> experiments further showed reduced inflammation and bone loss in locally irradiated (1 × 0.5Gy) paws. As factors secreted by inflammatory FLS modulate other immune cells, we now aimed to investigate their impact on macrophages (MPHs) that are key players in inflammation and also major producers of inflammatory cytokines. Further, as bone turnover is a tightly linked process between bone resorption and build-up, we subsequently aimed to investigate whether and how LD-RT impacts on osteoblasts. <h3>Material and methods</h3> Bone marrow-derived MPHs of h<i>TNF-α</i> tg mice were differentiated using M-CSF and supernatants of X-ray treated FLS. Consecutively, MPH phenotypes were analysed by flow cytometry and ELISA. h<i>TNF-α</i> tg-derived osteoblasts were irradiated with various doses of X-rays and the impact of radiation was analysed using alizarin-red, qPCR and ELISA. <h3>Results</h3> Treatment of MPHs with supernatants of irradiated FLS lead to decreased CD86 (0.5-2Gy) and MHCII (0.1–0.5Gy) surface expression, while secreted IL-10 levels were increased at 0.5Gy. LD-RT of osteoblasts led to increased mineralization at a dose of 0.5Gy, a dose dependent increase in expression levels of osteoblast maturation markers, and reduced Rank-L expression, alongside with increased secretion of osteoprotegerin. <h3>Conclusion</h3> We conclude that LD-RT is able to positively modulate bone-turnover and exerts anti-inflammatory effects on FLS and MPHs. In accordance with our previous results, these modulations might contribute to improvements in TNF-driven RA. In the future, placebo controlled studies are desirable in order to investigate the effects of LD-RT in RA and osteoimmunological events in the clinics. <h3>Acknowledgement</h3> Supported by the German Federal Ministry of Education and Research (GREWIS, 02NUK017G).
接合部接着分子A標的マイクロバブルの超音波ガイド下イメージングはウサギにおける脆弱性プラークを同定する【Powered by NICT】
Authors: Zhang Ya-Jun, Bai Dan-Na, Du Jing-Xi, Jin Liang, Ma Jing, Yang Jia-Lei, Cai Wen-Bin, Feng Yang, Xing Chang-Yang, Yuan Li-Jun, Duan Yun-You
Journal: Biomaterials (2016)
Identifying tumor vascular genes regulated by Aflibercept (VEGF Trap)
Authors: Alexander Adler, Alexandra Eichten, Chiayi Kao, Yi Wei, Wen Fury, Calvin Lin, Gavin Thurston
Journal: Cancer Research (2008)

2497  VEGF blockade has been shown to be effective at inhibiting tumor growth in various preclinical models and in diverse human cancers. Treatment of tumors with VEGF blockers results in a rapid loss of tumor vessels and changes in the phenotype of the tumor vessels, including decrease sprouting and branching. In this study, we sought to characterize in more detail the rapid changes in tumor vessels following VEGF blockade, by identifying vascular genes that are under direct regulation by VEGF in tumors. SCID mice bearing established tumors of different origins (two human renal cell carcinomas (786-0, A498), a human and a rat glioblastoma (U87-MG, C6), and a human colorectal carcinoma (Colo205) were treated with a single subcutaneous dose of aflibercept (VEGF Trap, 25 mg/kg), a potent inhibitor of all isoforms of VEGF-A and placental growth factor (PlGF) that is currently in Phase III clinical trials. At 8, 24 or 72 hr after treatment, tumors were excised and divided in half with one half processed for gene expression analysis, and the other half stained by immunohistochemistry for blood vessels (PECAM/CD31) and measured morphometrically for tumor vessel density. We found that expression levels of a number of vascular genes, including ICAM2, eNOS, and VE-cadherin, were decreased by VEGF Trap at 24 and 72 hr, but not at 8 hr. The time course and magnitude of the reduced expression of these genes correlated with the decrease in vessel density in the different tumor types, thus these genes may serve as markers of tumor vessel density. In comparison, expression levels of several other vascular genes, including Angiopoietin-2 and Nidogen2, were already decreased at 8 hr after treatment of multiple tumor types with VEGF Trap, and remained decreased at 24 and 72 hr. Expression of these latter genes appears to be dependent upon continued VEGF signaling, suggesting that these represent direct VEGF target genes. These results show that at least 2 phases of vascular gene expression changes can be discerned in tumors following VEGF blockade: the initial phase involves VEGF target genes and the latter phase involves constitutive endothelial cells genes. The most rapidly changed genes may provide biomarkers of VEGF-blockade, whereas the slower changing genes may be useful as indicators of overall tumor vascularity.
Proximodistal Heterogeneity of Hippocampal CA3 Pyramidal Neuron Intrinsic Properties, Connectivity, and Reactivation during Memory Recall
Authors: Qian Sun, Alaba Sotayo, Alejandro S. Cazzulino, Anna M. Snyder, Christine A. Denny, Steven A. Siegelbaum
Journal: Neuron (2017)
Generalized Lymph Node FDG Uptake as the First Manifestation of Systemic Lupus Erythematosus
Authors: Antoine Girard, Jessica Ohnona, Jean-François Bernaudin, Françoise Montravers, Claude Bachmeyer
Journal: Clinical Nuclear Medicine (2017)

We report 2 cases of young patients referred for FDG PET/CT for peripheral lymphadenopathy and moderate fever associated with pericarditis in 1 patient and glomerulonephritis in the other patient. FDG PET/CT showed a very similar appearance in these 2 patients, with highly avid lymph nodes with axillary predominance and diffuse FDG uptake in spleen and bone marrow. Systemic lupus erythematosus with an unusual presentation of generalized lymphadenopathy was diagnosed in both patients. This FDG distribution pattern should be kept in mind when PET is performed for etiological investigation of fever of unknown origin.
28 Sensitivity of clo testing in the northern trust
Authors: P Rooney, O Omotoso, G Manikpure
Journal: Gut (2017)

Background  Helicobacter pylori is a gram negative organism commonly found in the stomach. The majority of patients infected don’t experience any symptoms or complications however it can be associated with PUD, Gastric MALT Lymphoma, Gastric Cancer and chronic gastritis. We usually diagnose H. Pylori with the use of CLO testing at endoscopy.  Aim  We wanted to assess the sensitivity of these kits after a number of “negative” CLO tests had H. pylori confirmed at histology. This is important given the carcinogenic properties of H. Pylori.  Method  This was a retrospective analysis of every CLO test that was performed between 01/08/16 and 31/10/16. For each patient that had a CLO test we checked the lab system for histology samples to check for any disparity. We also recorded the diagnosis at oesophagogastroduodenoscopy (OGD) and whether or not the patient was taking PPI medications.  Results  179 OGDs with CLO tests were performed in the specified time period. 11/179 were CLO positive (6.1%). 25/179 samples were sent for histology. 5/25 were CLO negative, histology positive. 2 of these patients were on a PPI. 19/25 were CLO negative, histology negative. 1 patient was CLO positive, histology positive.  Conclusions  In a 3 month period, 5 cases of H. pylori would have been missed if histology wasn’t sent. The diagnostic yield for H pylori at histology was 24% compared to 6.1% with CLO testing. Given the carcinogenic properties of H. pylori we are now recommending that samples should be sent to histology in addition to CLO testing, if H. pylori is suspected.